Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stomach recovery time after GLP-1 drugs measured in surgery patients

NCT ID NCT07360262

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 186 adults taking GLP-1 RA drugs (like Ozempic) who were scheduled for surgery. Researchers used ultrasound to measure stomach contents at different times after the last dose. The goal was to find out how long it takes for stomach emptying to return to normal, helping doctors decide when it's safe to stop these drugs before anesthesia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

186 people

The number who actually took part.

Started

Nov 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients receiving GLP-1 receptor agonists who were scheduled for elective surgery under general anesthesia at a tertiary academic hospital and underwent preoperative point-of-care gastric ultrasound immediately prior to induction of anesthesia.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults aged ≥18 years * Receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA) * Scheduled for elective surgery under general anesthesia * Able to provide written informed consent Exclusion Criteria * Prior gastric or esophageal surgery * Known gastroparesis * Severe gastroesophageal reflux disease * Emergency surgery * Pregnancy * Inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric emptying are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wonkwang University Hospital

    Iksan, Jeollabuk-do, 54538, South Korea

  • Wonkwang University School of Medicine Hospital

    Iksan, Jeollabuk-do, 54538, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.